Industry Radar

What have been key developments thus far in 2020 impacting API sourcing, and how may that affect manufacturing networks and supply lines going forward? From plans to increase domestic drug…

The FDA finalized a rule last month as part of a plan for the safe importation of drugs from Canada into the US. The rule is part of the Safe…

The quest for vaccines and treatments against COVID-19 has put the CEOs of certain companies, both large and small, on the industry’s radar. The CEOs of J&J, AstraZeneca, Pfizer, Moderna,…

How are biologics faring in terms of new drug approvals? DCAT Value Chain Insights examines biologic-based APIs approved as new molecular entities by the FDA’s Center for Drug Evaluation and…

What are the latest developments in upstream and downstream bioprocessing? DCAT Value Chain Insights provides a roundup of CDMO/CMO expansions in biomanufacturing and manufacturing for cell and gene therapies. CDMO/CMO…

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how…

What are the key developments from the large pharmaceutical companies’ pipelines expected for later this year? Which new drugs or additional indications for existing drugs have blockbuster potential? DCAT Value…

The UK and the European Union (EU) are resuming negotiations this week (September 29 to October 2, 2020) for a deal that would define the UK’s future relationship with the…

The rise in the number of orphan-drug approvals and an increase in the development of more targeted therapies with smaller patient populations results in lower-volume drugs. What is the impact…

Buoyed by $2 billion in funding by the private equity firm, Blackstone, a $1-billion partnering deal with Regeneron Pharmaceuticals, and potential gains from a possible blockbuster anti-cholesterol drug it has…